Novo Nordisk’s $50 Price Frames a Value Versus Value Trap Debate

Novo Nordisk trades near $50, down 75% from its June 2024 peak of $142.44, caught between a turnaround narrative and structural decline thesis. The stock has recovered from $35 lows on the back of a blockbuster oral Wegovy pill launch and Q1 earnings beat, but faces persistent headwinds from Eli Lilly's competitive dominance in GLP-1 drugs, pipeline setbacks with CagriSema, US pricing pressure, and patent erosion. At 11.8x forward earnings with a 3.6% dividend yield, the market is divided on whether the stock represents genuine value or a value trap.